Virtual Library

Start Your Search

L. Mas



Author of

  • +

    P1.01 - Poster Session with Presenters Present (ID 453)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Epidemiology/Tobacco Control and Cessation/Prevention
    • Presentations: 1
    • +

      P1.01-050 - Overall Survival in Advanced Lung Cancer Patients Treated at Oncosalud-AUNA (ID 6336)

      14:30 - 15:45  |  Author(s): L. Mas

      • Abstract

      Background:
      Lung cancer still remains as the principal death cause in many regions around the world. Unfortunate, between 60-70% of patients are diagnosed with advanced disease (clinical stage IIIB-IV). We report the overall survival of advanced lung cancer in patients treated at a private institution (Oncosalud – AUNA).

      Methods:
      We analyzed data of 75 patients with advanced lung cancer and treated at Oncosalud-AUNA between 2013-2014. Overall survival was determinate using Kaplan-Meier method and survival curves comparison were performed using logrank test.

      Results:
      The median age was 70 years (range: 39-91) and 49% of patients were women. In patients with clinical stage IV, the metastatic sites were generally brain (28%), osseous (18%), cervical and supraclavicular (14%). The 66.7% of patients received chemotherapy with/without radiotherapy, 9% radiotherapy only and 24% non-treatment. In patients previously treated with chemotherapy, 52% received targeted therapy. The 77% of patients hab died, the follow-up median of survivors was 23 months (CI95%: 17-29), survival median was 9.6 months (CI95%. 5.6-13.5) and 1 and 2 years survival rate were 38% and 23%, respectively. The survival rate at 1 and 2 years in those receiving targeted therapy ware 65% and 43%, and those who did not receive were 35% and 10%. The overall survival present a difference regarding to ECOG scale (p = 0.015) and CYFRA 21.2 (p = 0.04).

      Conclusion:
      Overall survival for our patients is similar to other series. Patients under ECOG scale <2 and CYFRA 21.1 < 3.3ng/ml had a relatively better prognostic.